Product Description
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Phoenix Molecular Imaging
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Prostate Cancer
Phase 1: Prostate Cancer|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2014-01203 | N/A |
Withdrawn |
Prostate Cancer |
2018-11-01 |
2019-03-20 |
Treatments |
|
| ChoPEN | N/A |
Unknown status |
Prostate Cancer |
2014-01-01 |
2019-03-19 |
Treatments |
|
| CDR0000434994 | N/A |
Completed |
Prostate Cancer |
2010-07-01 |
2019-03-21 |
Treatments |
|
| NCT01777061 | N/A |
No longer available |
Prostate Cancer |
None |
2019-03-19 |
Treatments |
|
| ACETATE16-000260EA | N/A |
No longer available |
Prostate Cancer |
None |
2019-04-24 |
Treatments|Trial Status |
|
| [11C]Butanol | P1 |
Completed |
Healthy Volunteers |
2020-12-29 |
2021-06-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| NCT01144897 | P1 |
Completed |
Prostate Cancer |
2011-11-01 |
2019-03-19 |
||
| AMIC-AC-002 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2019-01-01 |
2019-03-19 |
Treatments |
|
| AMIC-AC-001 | P2 |
Completed |
Prostate Cancer |
2019-01-01 |
2019-03-19 |
Treatments |